Summary
Definition
History and exam
Other diagnostic factors
- altered mental status
- headache
- nausea and/or vomiting
- gait abnormality
- ataxia
- weakness
- seizures
- visual disturbances
- speech deficit
- aphasia/dysphasia
- sensory deficit
- motor weakness
- visual change
- cranial nerve palsy
- papilledema
- personality change/emotional lability
Risk factors
- white ancestry
- male sex
- neurofibromatosis type 1
- tuberous sclerosis complex
- Li-Fraumeni syndrome
- Turcot syndrome
- ionizing radiation
Diagnostic tests
1st tests to order
- MRI head
- ophthalmologic evaluation; visual field testing
- CT head
- brain MR spectroscopy
- brain perfusion MRI
- histopathology
- molecular analyses
Tests to consider
- pituitary hormones tests
- diffusion tensor imaging (DTI)
Emerging tests
- 2-hydroxyglutarate-targeted magnetic resonance spectroscopy
Treatment algorithm
elevated intracranial pressure or vasogenic edema
circumscribed glioma: pilocytic/pilomyxoid astrocytoma (World Health Organization [WHO] grade 1)
circumscribed glioma: subependymal giant cell astrocytoma (WHO grade 1)
circumscribed glioma: pleomorphic xanthoastrocytoma (WHO grade 2)
diffuse infiltrating glioma: grade 2
diffuse infiltrating glioma: grades 3 and 4
diffuse midline glioma, H3 K27M-altered
recurrent circumscribed glioma
progressive diffuse infiltrating glioma
Contributors
Authors
L. Nicolas Gonzalez Castro, MD, PhD
Instructor in Neurology
Center for Neuro-Oncology
Dana-Farber Cancer Institute and Brigham and Women's Hospital
Harvard Medical School
Boston
MA
Disclosures
LNGC has received consulting fees from Elsevier, Oakstone Publishing, and Teladoc. LNGC has received research funding from Merck & Co. (to Dana-Farber Cancer Institute). LNGC is an author of a number of references cited in this topic.
Acknowledgements
Dr L. Nicolas Gonzalez Castro would like to gratefully acknowledge Dr Timothy C. Ryken, Dr Linton T. Evans, Dr Manmeet S. Ahluwalia, Dr Susan Chang, and Dr Karine Michaud, previous contributors to this topic.
Disclosures
TCR is an author of a number of references cited in this topic. MSA has acted as a consultant for Elekta, Incyte, AstraZeneca, Novocure, Caris Life Sciences, Bristol-Myers Squibb, Monteris Medical, AbbVie, MRI Solutions, Elsevier, and Prime oncology. MSA has received clinical trial investigations grants from Tracon, Bristol-Myers Squibb, AstraZeneca, Novartis, and Novocure. SC has received research support from Agios, Novartis, Quest, Roche, and Schering Plough. KM and LTE declare that they have no competing interests.
Peer reviewers
David A. Reardon, MD
Associate Professor
The Preston Robert Tisch Brain Tumor Center
Duke University Medical Center
Durham
NC
Disclosures
DAR declares that he has no competing interests.
Differentials
- Brain metastasis
- Brain abscess
- Multiple sclerosis
More DifferentialsGuidelines
- NCCN clinical practice guidelines in oncology: central nervous system cancers
- Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline
More Guidelines- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer